An ongoing study of a CAIX-targeted CAR-T regimen in advanced ccRCC involves girentuximab delivery into the hepatic artery prior to CAR-T infusion, aiming to minimize potential hepatotoxicity (NCT04969354). The gene discussed is CA9; the disease is nonpapillary renal cell carcinoma.